article thumbnail

Biotech startup Ray raises $100M for vision-restoring gene therapies

Bio Pharma Dive

Founded in early 2021, the company is using optogenetics to design treatments that could work across disease genotypes and in the later stages of vision loss.

article thumbnail

SSRgenotyper: A new tool to digitally genotype simple sequence repeats

Scienmag

SSRgenotyper: A simple sequence repeat genotyping application for whole-genome resequencing and reduced representational sequencing projects.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Predicting multi-omics from genotypes with OmicsPred

Medical Xpress

Work by an international research team led by Yu Xu and Michael Inouye at the Department of Public Health and Primary Care, University of Cambridge, has resulted in a unique resource for predicting multi-omics data directly from genotypes.

article thumbnail

NHS to test new blood group genotyping test on inherited blood disorder patients

Pharma Times

Patients living with sickle cell disease and thalassaemia will be eligible for the test

Genotype 119
article thumbnail

Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention

Medical Xpress

A new research paper titled "Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention" has been published in Oncotarget.

article thumbnail

Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China

Pharmaceutical Technology

Given subcutaneously, the antibody can hinder the entry of all ten HBV genotypes into hepatocytes and can also lower virion and subviral particle levels in the blood. A widely neutralising monoclonal antibody (mAb), VIR-3434 (BRII-877) acts on the hepatitis B virus (HBV). The mAb is presently in the Phase II development stage.

Antibody 279
article thumbnail

FDA grants approval for bluebird’s Zynteglo to treat beta-thalassemia

Pharmaceutical Technology

0 genotypes. The latest approval is based on findings from the Phase III clinical trials, HGB-207 (Northstar-2) and HGB-212 (Northstar-3), and the long-term follow-up LTF-303 study. The open-label, single-arm, 24-month Phase III trials enrolled 41 subjects of the age four to 34 years with non-?0/?0